The Experts below are selected from a list of 211059 Experts worldwide ranked by ideXlab platform
Giuseppe Giaccone - One of the best experts on this subject based on the ideXlab platform.
-
Tyrosine kinase inhibitors in lung Cancer.
Hematology-oncology Clinics of North America, 2012Co-Authors: Anish Thomas, Arun Rajan, Giuseppe GiacconeAbstract:‘Driver mutations’ are essential for carcinogenesis as well as tumor progression as they confer a selective growth advantage to Cancer cells. Identification of driver mutations in growth related protein kinases, especially tyrosine kinases have led to clinical development of an array of tyrosine kinase inhibitors in various malignancies, including lung Cancer. Inhibition of epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinases have proven to be of meaningful clinical benefit, while Inhibition of several other tyrosine kinases have been of limited clinical benefit, thus far. An improved understanding of tyrosine kinase biology has also led to faster drug development, identification of resistance mechanisms and ways to overcome resistance. In this review, we discuss the clinical data supporting the use and practical aspects of management of patients on epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors.
Anish Thomas - One of the best experts on this subject based on the ideXlab platform.
-
Tyrosine kinase inhibitors in lung Cancer.
Hematology-oncology Clinics of North America, 2012Co-Authors: Anish Thomas, Arun Rajan, Giuseppe GiacconeAbstract:‘Driver mutations’ are essential for carcinogenesis as well as tumor progression as they confer a selective growth advantage to Cancer cells. Identification of driver mutations in growth related protein kinases, especially tyrosine kinases have led to clinical development of an array of tyrosine kinase inhibitors in various malignancies, including lung Cancer. Inhibition of epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinases have proven to be of meaningful clinical benefit, while Inhibition of several other tyrosine kinases have been of limited clinical benefit, thus far. An improved understanding of tyrosine kinase biology has also led to faster drug development, identification of resistance mechanisms and ways to overcome resistance. In this review, we discuss the clinical data supporting the use and practical aspects of management of patients on epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors.
Peter J. O’dwyer - One of the best experts on this subject based on the ideXlab platform.
-
Antiangiogenic tyrosine kinase inhibitors in colorectal Cancer: is there a path to making them more effective?
Cancer Chemotherapy and Pharmacology, 2017Co-Authors: Thomas B. Karasic, Mark A. Rosen, Peter J. O’dwyerAbstract:Antiangiogenic therapy has a proven survival benefit in metastatic colorectal Cancer. Inhibition of the VEGF pathway using a variety of extracellular antibody approaches has clear benefit in combination with chemotherapy, while intracellular blockade using tyrosine kinase inhibitors (TKIs) such as sorafenib and regorafenib has had more limited success. Pharmacodynamic modeling using modalities such as DCE-MRI indicates potent antiangiogenic effects of these TKIs, yet numerous combination therapies, primarily with chemotherapy, have failed to demonstrate an additive benefit. The sole comparative study of a single agent TKI against placebo showed a survival benefit of regorafenib in patients with advanced, refractory disease. Preclinical data demonstrate synergy between antiantiogenic TKIs and targeted interventions including autophagy Inhibition, and together with a renewed effort to define markers of susceptibility, such combinations may be a way to improve the limited efficacy of this once-promising drug class.
Chung S. Yang - One of the best experts on this subject based on the ideXlab platform.
-
Murine Prostate Cancer Inhibition by Dietary Phytochemicals—Curcumin and Phenyethylisothiocyanate
Pharmaceutical research, 2008Co-Authors: Avantika Barve, Tin Oo Khor, Xingpei Hao, Young-sam Keum, Chung S. Yang, Bandaru S. Reddy, Ah-ng Tony KongAbstract:Purpose Prior studies from our laboratory have demonstrated the efficacy of a combined treatment of low doses of dietary agents curcumin and phenylethylisothiocyanate in effectively suppressing prostate Cancer in vitro in human prostate Cancer PC3 cells as well as in vivo in immunodeficient mice implanted with PC3 cells. Hence, this study was undertaken to examine the potential chemopreventive properties of the two agents against transgenic adenocarcinoma of the mouse prostate.
-
Inhibition of carcinogenesis by tea
Nature, 1997Co-Authors: Chung S. YangAbstract:In the recent Scientific Correspondence1 by J. Jankun et al., entitled “Why drinking tea could prevent Cancer”, I was surprised to find that a review article by myself and Z.-Y. Wang about the effects of green and black tea on Cancer2 had been misquoted. In addition, I find the hypothesis in this report as to why drinking tea could prevent Cancer misleading, and believe that the data were erroneously interpreted with regard to the mechanisms of Cancer Inhibition by tea. I would like to clarify four points.
Jaana Hagström - One of the best experts on this subject based on the ideXlab platform.
-
Predictive role of toll-like receptors 2, 4, and 9 in oral tongue squamous cell carcinoma
Oral oncology, 2014Co-Authors: Laura K. Mäkinen, Timo Atula, Valtteri Häyry, Lauri Jouhi, Neeta Datta, Sanna Lehtonen, Abdirisak Ahmed, Antti Mäkitie, Caj Haglund, Jaana HagströmAbstract:summary Objectives: The clinical behavior of oral tongue squamous cell carcinoma (OTSCC) can be unpredictable, and even small tumors may behave aggressively. Toll-like receptors (TLRs) are pattern-recognition molecules involved in innate immunity, and they are also expressed in many types of Cancer. TLRs play an apparently pivotal role in some Cancers related to tumor progression and, conversely, Cancer Inhibition, however their role in oral Cancer is unclear. We therefore studied the expression of TLR-2, -4, -5, -7, and -9 in early-stage OTSCC.
